Treatment of post-transplant lymphoproliferative disorder with monoclonal cd20 antibody (rituximab) after heart transplantation

Nathan D. Zilz, Lyle J. Olson, Christopher G. McGregor

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Post-transplant lymphoproliferative disorder (PTLD) is a frequent and often fatal complication of organ transplantation. It most often results from an Epstein-Barr virus (EBV)-transformed B-cell clone, which expresses B-cell surface markers such as CD20. We describe a case of a heart transplant recipient who EBV seroconverted post-transplant and subsequently developed subcutaneous and lymphatic B-cell lymphoma, successfully treated with CD20 antibody (rituximab). The patient has been in remission during 10 months of clinical follow-up.

Original languageEnglish (US)
Pages (from-to)770-772
Number of pages3
JournalJournal of Heart and Lung Transplantation
Volume20
Issue number7
DOIs
StatePublished - 2001

Fingerprint

Lymphoproliferative Disorders
Heart Transplantation
Human Herpesvirus 4
B-Lymphocytes
Monoclonal Antibodies
Transplants
Organ Transplantation
B-Cell Lymphoma
Clone Cells
Therapeutics
Rituximab
Transplant Recipients

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Transplantation

Cite this

Treatment of post-transplant lymphoproliferative disorder with monoclonal cd20 antibody (rituximab) after heart transplantation. / Zilz, Nathan D.; Olson, Lyle J.; McGregor, Christopher G.

In: Journal of Heart and Lung Transplantation, Vol. 20, No. 7, 2001, p. 770-772.

Research output: Contribution to journalArticle

@article{fca86b77a765458eb334bc8b15e74f4e,
title = "Treatment of post-transplant lymphoproliferative disorder with monoclonal cd20 antibody (rituximab) after heart transplantation",
abstract = "Post-transplant lymphoproliferative disorder (PTLD) is a frequent and often fatal complication of organ transplantation. It most often results from an Epstein-Barr virus (EBV)-transformed B-cell clone, which expresses B-cell surface markers such as CD20. We describe a case of a heart transplant recipient who EBV seroconverted post-transplant and subsequently developed subcutaneous and lymphatic B-cell lymphoma, successfully treated with CD20 antibody (rituximab). The patient has been in remission during 10 months of clinical follow-up.",
author = "Zilz, {Nathan D.} and Olson, {Lyle J.} and McGregor, {Christopher G.}",
year = "2001",
doi = "10.1016/S1053-2498(00)00326-0",
language = "English (US)",
volume = "20",
pages = "770--772",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "7",

}

TY - JOUR

T1 - Treatment of post-transplant lymphoproliferative disorder with monoclonal cd20 antibody (rituximab) after heart transplantation

AU - Zilz, Nathan D.

AU - Olson, Lyle J.

AU - McGregor, Christopher G.

PY - 2001

Y1 - 2001

N2 - Post-transplant lymphoproliferative disorder (PTLD) is a frequent and often fatal complication of organ transplantation. It most often results from an Epstein-Barr virus (EBV)-transformed B-cell clone, which expresses B-cell surface markers such as CD20. We describe a case of a heart transplant recipient who EBV seroconverted post-transplant and subsequently developed subcutaneous and lymphatic B-cell lymphoma, successfully treated with CD20 antibody (rituximab). The patient has been in remission during 10 months of clinical follow-up.

AB - Post-transplant lymphoproliferative disorder (PTLD) is a frequent and often fatal complication of organ transplantation. It most often results from an Epstein-Barr virus (EBV)-transformed B-cell clone, which expresses B-cell surface markers such as CD20. We describe a case of a heart transplant recipient who EBV seroconverted post-transplant and subsequently developed subcutaneous and lymphatic B-cell lymphoma, successfully treated with CD20 antibody (rituximab). The patient has been in remission during 10 months of clinical follow-up.

UR - http://www.scopus.com/inward/record.url?scp=0034946298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034946298&partnerID=8YFLogxK

U2 - 10.1016/S1053-2498(00)00326-0

DO - 10.1016/S1053-2498(00)00326-0

M3 - Article

VL - 20

SP - 770

EP - 772

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 7

ER -